Skip to content
Clinical Trials – home
Not recruiting

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for metastatic colorectal cancer, which is a type of cancer that starts in the colon or rectum and spreads to other parts of the body. The study involves two sequences of treatment using combinations of chemotherapy and biologic drugs. The chemotherapy regimens are known as FOLFOX and FOLFIRI. FOLFOX includes drugs like folinic acid, oxaliplatin, and fluorouracil, while FOLFIRI includes folinic acid, irinotecan, and fluorouracil. The biologic drugs used in this study are panitumumab and bevacizumab, which are designed to target specific proteins involved in cancer growth.

The purpose of the study is to compare the effectiveness of two different sequences of these treatments. In the first sequence, patients receive FOLFOX combined with panitumumab, followed by FOLFIRI combined with bevacizumab. In the second sequence, patients receive FOLFOX combined with bevacizumab, followed by FOLFIRI combined with panitumumab. The study aims to determine which sequence is more effective in controlling the cancer over a period of 36 months.

Participants in the study will receive their treatments through intravenous infusions, which means the medication is delivered directly into the bloodstream through a vein. The study will monitor the progression of the cancer and the overall survival of the patients over the course of the treatment. The trial will also assess the safety of the treatments by keeping track of any side effects experienced by the participants. The study is expected to continue until June 2025.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization and first treatment sequence

    After joining the study, you are randomized, which means you are assigned by chance to one of two treatment sequences.

    In Sequence 1, you first receive FOLFOX with panitumumab. FOLFOX is a combination of oxaliplatin 85 mg/m2, folinic acid 200 mg/m2, and fluorouracil 400 mg/m2, all given by intravenous use (through a vein). Panitumumab is given at 6 mg/kg by intravenous use.

    In Sequence 2, you first receive FOLFOX with bevacizumab. FOLFOX includes oxaliplatin 85 mg/m2, folinic acid 200 mg/m2, and fluorouracil 400 mg/m2, all given by intravenous use. Bevacizumab is given at 5 mg/kg by intravenous use.

    Your condition is followed during this first treatment period to see whether the cancer does not get worse, whether it gets smaller, and whether you have any side effects.

  2. Step 2

    Change to the second treatment sequence

    After the first treatment sequence, you move to the second treatment sequence.

    In Sequence 1, the second treatment is FOLFIRI with bevacizumab. FOLFIRI is a combination of irinotecan 180 mg/m2 and fluorouracil 400 mg/m2, both given by intravenous use. Folinic acid is not listed as part of the source data for FOLFIRI in this study information. Bevacizumab is given at 5 mg/kg by intravenous use.

    In Sequence 2, the second treatment is FOLFIRI with panitumumab. FOLFIRI is a combination of irinotecan 180 mg/m2 and fluorouracil 400 mg/m2, both given by intravenous use. Folinic acid is not listed as part of the source data for FOLFIRI in this study information. Panitumumab is given at 6 mg/kg by intravenous use.

    This second treatment period is also used to assess whether the cancer gets worse, whether it responds to treatment, and whether any side effects occur.

  3. Step 3

    Follow-up and assessment period

    You continue to be followed after treatment starts so that the study can measure how long it takes before the cancer gets worse or causes death, how long the response lasts, and how often the cancer stays controlled.

    The study also checks the size of the cancer during treatment. A response means the cancer becomes smaller or disappears. Stable disease means the cancer does not clearly grow or shrink.

    At the first evaluation, which is at week 12, the study checks for early tumor shrinkage, meaning a reduction in cancer size of at least 30%.

  4. Step 4

    Safety monitoring throughout the study

    Throughout the study, your safety is monitored by checking for adverse events (unwanted medical problems), serious adverse events (severe unwanted medical problems), and laboratory safety results.

    Side effects are graded using a standard medical scale called NCI-CTCAE version 4.03, which is a system used to describe how mild or severe a side effect is.

  5. Step 5

    Study end point at 36 months

    At 36 months after randomization, the study checks whether you are alive and whether the cancer has not progressed. Progression means the cancer has gotten worse.

    This time point is used to compare the two treatment sequences and to measure the main outcome of the study.

Who can join the trial?

12 criteria

  • Be an adult, meaning 18 years of age or older.
  • Be able to understand the study information, and be willing and able to sign and date the informed consent form, which is the document that gives permission to join the study.
  • Have a confirmed diagnosis of adenocarcinoma of the left colon or rectum. This means the cancer must start in the splenic flexure, descending colon, sigmoid colon, or rectum.
  • Have metastatic disease that is unresectable or not potentially resectable, meaning the cancer has spread and cannot be removed with surgery aimed at curing the metastases at the time of study entry.
  • Have wild-type RAS confirmed before starting first-line treatment. Wild-type means the RAS gene does not have the specific mutations being checked for. The testing must include at least KRAS exons 2, 3, and 4 and NRAS exons 2, 3, and 4.
  • Have at least one measurable tumor lesion, meaning at least one area of cancer that can be measured on scans according to RECIST 1.1, a standard way to measure tumors in studies.
  • Have an ECOG performance status below 2. This is a score that shows how well a person can do daily activities; a score below 2 means the person is able to carry out most self-care and is not confined to bed or a chair for most of the day.
  • Have adequate bone marrow function, meaning the body is making enough blood cells: neutrophils at least 1.5 × 109/L, platelets at least 100 × 109/L, and hemoglobin at least 9 g/dL. Neutrophils are white blood cells that help fight infection, platelets help blood clot, and hemoglobin carries oxygen in the blood.
  • Have adequate liver, kidney, and metabolic function, including:
    • Total bilirubin no more than 1.5 times the upper limit of normal. Bilirubin is a substance made when the body breaks down old red blood cells.
    • ALT and AST no more than 2.5 times the upper limit of normal. These are liver enzymes that can rise when the liver is injured or stressed.
    • If the cancer has spread to the liver, ALT and AST may be up to 5 times the upper limit of normal.
    • Kidney function with creatinine clearance or 24-hour creatinine clearance of at least 50 mL/min. Creatinine clearance is a test that shows how well the kidneys remove waste from the blood.

Who cannot join the trial?

28 criteria

  • Any past or current spread of cancer to the central nervous system (the brain and spinal cord).
  • Any other primary cancer in the past, except for: cervical cancer found very early and treated with cure, non-melanoma skin cancer removed with cure, or another solid tumor that was treated with cure, has no known active disease, and did not need treatment for at least 5 years before randomization.
  • Previous chemotherapy or other whole-body cancer treatment for metastatic colorectal cancer, including treatment given after surgery for stage IV disease.
  • Previous adjuvant chemotherapy for colorectal cancer (stage I, II, or III) that ended less than 6 months before the metastatic disease was found.
  • Any side effects from a previous whole-body treatment that have not gone away and, in the investigator’s opinion, make the patient unfit for the study.
  • Any previous use of anti-EGFR treatment, such as cetuximab, or anti-VEGF treatment, or small molecule tyrosine kinase inhibitors such as regorafenib. These are cancer drugs that block specific growth signals.
  • Any approved or experimental cancer treatment within 30 days before joining the study. Hormone replacement treatment is allowed.
  • Serious heart or blood vessel disease, including unstable angina (chest pain not under control), myocardial infarction (heart attack) within the last 12 months, or a history of ventricular arrhythmia (an abnormal heart rhythm from the lower chambers of the heart).
  • Uncontrolled hypertension (high blood pressure that is not well managed).
  • History of interstitial pneumonitis or pulmonary fibrosis, or signs of these lung problems on the starting chest CT scan (a detailed imaging test using X-rays).
  • Treatment for a systemic infection within 14 days before the study treatment starts. A systemic infection is an infection that affects the whole body.
  • Active intestinal occlusion (a blocked bowel), active inflammatory bowel disease, or another bowel disease causing long-lasting diarrhoea of at least grade 2. Grade 2 means moderate diarrhoea that is more than mild and can affect daily life.
  • Significant peripheral sensory neuropathy, which means nerve damage causing numbness, tingling, or pain, usually in the hands or feet.
  • Any past allergic reaction, of any severity, to any part of the study treatment.
  • A known mutation in the UGT1A1 gene, or known dihydropyrimidine deficiency syndrome. These are inherited conditions that affect how the body handles certain medicines.
  • An active or uncontrolled gastroduodenal ulcer within the last 6 months. This is a sore in the stomach or the first part of the small intestine.
  • A pulmonary embolism (blood clot in the lung), deep vein thrombosis (blood clot in a deep vein, usually in the leg), or another significant venous event within the last 6 months.
  • A bleeding tendency or coagulopathy (a problem with blood clotting), except for well-controlled blood thinner treatment within the last 6 months.
  • A major surgery, open biopsy, or major injury within 28 days before study entry, or not yet fully recovered from a previous major surgery. Minor procedures such as diagnostic biopsy, central venous catheter placement, or colonic stent placement are not included in this restriction.
  • Any other illness that may raise the risks of taking part in the study or may make the study results hard to interpret.
  • Known positive test for HIV (human immunodeficiency virus), hepatitis C virus, or chronic active hepatitis B infection.
  • Any problem that prevents the patient from giving written informed consent or from following the study rules. Informed consent means clearly agreeing to take part after understanding the study.
  • Use of any investigational agent within 30 days before joining the study. An investigational agent is a treatment still being tested.
  • Pregnancy or breastfeeding.
  • Full-dose radiotherapy within 28 days before study entry. Radiotherapy is treatment with radiation. Short-course radiotherapy for local control or symptom relief is allowed.
  • For men and women who can have children: not agreeing to use reliable contraception during the study and for 6 months after the last dose of study medicine, or not agreeing to abstain from sex during that time. Double-barrier contraception means using two barrier methods, such as a diaphragm plus condoms.
  • Not willing or not able to meet the study requirements.
  • Psychological, travel-related, family, or social situations that could prevent following the study plan and follow-up visits.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Irinotecan

    is a cancer medicine given through a vein. In this trial, it is used as part of the FOLFIRI treatment plan to help slow or stop the growth of colorectal cancer cells.

  • Fluorouracil

    is a cancer medicine given through a vein. It is part of the FOLFIRI and FOLFOX treatment plans and works by interfering with how cancer cells make new genetic material, which can help stop them from growing.

  • Panitumumab

    is a targeted cancer therapy given through a vein. It is designed to block a protein on some cancer cells that helps them grow, which may help the treatment work better in patients whose tumors match this treatment.

  • Bevacizumab

    is a targeted cancer therapy given through a vein. It helps block the growth of new blood vessels that tumors need to grow and spread, which can help slow the cancer down.

  • Oxaliplatin

    is a cancer medicine given through a vein. It is part of the FOLFOX treatment plan and helps damage cancer cells so they cannot grow and divide as easily.

  • Folinic acid

    is given through a vein together with fluorouracil in the FOLFOX and FOLFIRI treatment plans. It helps fluorouracil work better against the cancer cells.

What is already known about the treatment

  • Irinotecan

    Irinotecan is given by intravenous infusion, which means it is delivered directly into a vein by a healthcare professional. It is an approved cancer medicine that is widely used in medical practice and studied in many clinical trials, especially for colorectal cancer. It is used to treat metastatic colorectal cancer and some other cancers because it helps slow or stop cancer growth by blocking an important enzyme called topoisomerase I, which cancer cells need to copy their DNA and divide. It belongs to the class of topoisomerase I inhibitors, a group of anticancer medicines that damage cancer cells more than normal cells during cell division.

  • Fluorouracil

    Fluorouracil is given by intravenous infusion and is administered by a medical team in a clinic or hospital. It is a long-established and well-known cancer medicine that remains important in modern oncology and is supported by extensive medical literature, especially for colorectal cancer. It is used to treat metastatic colorectal cancer and other cancers because it interferes with the way cells make DNA and RNA, which slows the growth of rapidly dividing cancer cells. Fluorouracil is classified as an antimetabolite, a type of anticancer medicine that acts like a natural building block of cells and disrupts cell growth.

  • Panitumumab

    Panitumumab is given by intravenous infusion as a concentrated solution for infusion, usually under close medical supervision. It is an approved targeted cancer medicine and is well described in medical literature, mainly for use in colorectal cancer with wild-type RAS. It is used to treat metastatic colorectal cancer because it attaches to a protein on the surface of cancer cells called EGFR and blocks signals that tell the cells to grow and survive. Panitumumab belongs to the class of monoclonal antibodies and is a targeted therapy.

  • Bevacizumab

    Bevacizumab is given by intravenous infusion and is administered by a healthcare professional. It is a well-established cancer medicine with broad use in clinical practice and strong support in medical literature, especially in solid tumors such as colorectal cancer. It is used to treat metastatic colorectal cancer because it blocks a protein called VEGF, which tumors use to form new blood vessels and get nutrients. Bevacizumab is classified as a monoclonal antibody and an anti-angiogenic medicine, meaning it helps stop tumors from building the blood supply they need to grow.

  • Oxaliplatin

    Oxaliplatin is given by intravenous infusion in a hospital or clinic setting. It is an approved and widely studied cancer medicine, especially in colorectal cancer treatment. It is used to treat metastatic colorectal cancer because it damages the cancer cell’s DNA, making it hard for the cell to copy itself and survive. Oxaliplatin belongs to the platinum-based anticancer medicines, a class that works by causing harmful links in DNA.

  • Folinic acid

    Folinic acid is given by intravenous infusion and is used as part of combination cancer treatment. It is a well-known medicine in clinical practice and medical literature, especially in regimens for colorectal cancer, where it is not used alone but helps other medicines work better. It is used to support treatment with fluorouracil because it increases fluorouracil’s effect on cancer cells by helping it bind more strongly to an enzyme needed for DNA making. Folinic acid is classified as a reduced folate, which is a vitamin-like substance used to enhance anticancer therapy.

Investigated diseases

Metastatic colorectal cancer - Metastatic colorectal cancer is cancer that starts in the colon or rectum and has spread to other parts of the body. It usually progresses by growing into nearby tissue first and then spreading through the blood or lymphatic system to distant organs such as the liver or lungs. As it advances, the cancer may form new tumors in multiple sites and gradually become more widespread.
Trial detailsLast updated 30 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-510967-41-00Protocol codeTTD-18-01Estimated enrolment416 patientsSponsorAsociacion Grupo Tratamiento De Tumores Digestivos

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.